Skip to main content
Psychopharmacology Bulletin › All Volumes & Issues › VOL 40 No. 3
PSYCHOPHARMACOLOGY BULLETIN

VOL 40 No. 3

Articles in This Issue

ORIGINAL RESEARCH

Defining the Clinical Course of Bipolar Disorder: Response, Remission, Relapse, Recurrence, and Roughening

Robert MA Hirschfeld, MD, Joseph R. Calabrese, MD, Mark A. Frye, MD, Philip W. Lavori, PhD, Gary Sachs, MD, Michael E. Thase, MD, and Karen Dineen Wagner, MD, PhD
Objective: This manuscript presents working definitions for key clinical course indicators for bipolar disorder, including response, remission, relapse, recurrence, and roughening. Method: A work group of experts in bipolar disorder reviewed prior efforts to define...
Pages 1-8 Read Article
ORIGINAL RESEARCH

Treatment Effects of Selegiline Transdermal System on Symptoms of Major Depressive Disorder: A Meta-Analysis of Short-Term, Placebo-Controlled, Efficacy Trials

Donald S. Robinson, MD, Michelle L. Gilmor, PhD, Ying Yang, PhD, George Moonsammy, PhD, Albert J. Azzaro, PhD, Dan A. Oren, MD, and Bryan J. Campbell, PharmD
Objective: Selegiline transdermal system (STS) is efficacious for the treatment of major depressive disorder (MDD). This meta-analysis explores treatment effects of STS for individual symptoms of MDD derived from line-item analyses of the 28-item Hamilton...
Pages 15-28 Read Article
COMMENTARY

Commentary on the Treatment Effects of Selegiline Transdermal System on Symptoms of Major Depressive Disorder: A Meta-Analysis of Short-Term, Placebo-Controlled, Efficacy Trials

Daniel J. Carlat, MD
There is increasing concern that reports of industry-sponsored research, such as “Treatment Effects of Selegiline Transdermal System on Symptoms of Major Depressive Disorder: A Meta-Analysis of Short-Term, Placebo-Controlled, Efficacy Trials” by Robinson and et al....
Pages 29-31 Read Article
NEGATIVE AND FAILED TRIAL REPORTS

An Open-Label Study of Tiagabine in Panic Disorder

David V. Sheehan, M.D., M.B.A, Kathy Harnett Sheehan, Ph.D, B. Ashok Raj, M.D, Juris Janavs, M.D
γ-Aminobutyric acid (GABA) has been implicated in the pathophysiology of anxiety disorders, including panic. Tiagabine, a selective GABA reuptake inhibitor (SGRI), has been shown to reduce symptoms of anxiety. This pilot study evaluated the efficacy...
Pages 32-40 Read Article
NEGATIVE AND FAILED TRIAL REPORTS

Adjunctive Risperidone in the Treatment of Generalized Anxiety Disorder: A Double-Blind, Prospective, Placebo-Controlled, Randomized Trial

Gahan J. Pandina, PhD, Carla M. Canuso, MD, Ibrahim Turkoz, MS, Mary Kujawa, MD, PhD, Ramy A. Mahmoud, MD, MPH
Background: Residual symptoms despite treatment are common in generalized anxiety disorder (GAD). The Patient-Rated Troubling Symptoms for Anxiety (PaRTS-A) is a newly created and validated instrument that measures the symptoms most troublesome to each individual...
Pages 41-54 Read Article
DRUG DISPOSITION & PHARMACOKINETICS

The Effect of Food on the Absorption of Oral Ziprasidone

Jeffrey J. Miceli, PhD, Paul Glue, MD, PhD, Jeffrey Alderman, PhD, and Keith Wilner, PhD
Objective: Oral ziprasidone bioavailability is known to increase when taken with food. Two pharmacokinetic studies were conducted to quantify the impact of food on ziprasidone absorption in healthy volunteers. Study 1: An open-label, six-way crossover...
Pages 58-59 Read Article
EVIDENCE-BASED MEDICINE

Concordance with Treatment Guidelines for Bipolar Disorder: Data from the Systematic Treatment Enhancement Program for Bipolar Disorder

Ellen B. Dennehy, PhD, Mark S. Bauer, MD, Roy H. Perlis, MD, Jane N. Kogan, PhD, and Gary S. Sachs, MD
Background: Concordance with evidence-based guidelines in the treatment of chronic mental disorders is typically low. This study assessed the degree of concordance with published treatment guidelines for bipolar disorder in the Systematic Treatment Enhancement Program...
Pages 72-84 Read Article
BRAIN IMAGING

Fear, Anxiety, and the Neuroimaging of PTSD

Eileen P. Ahearn, MD, PhD, Timothy Juergens, MD, Tracey Smith, PhD, Dean Krahn, MD, MS, and Ned Kalin, MD
The clinical manifestations of Posttraumatic Stress Disorder (PTSD) include both fear and anxiety symptoms. Animal studies provide significant information about the neurobiological pathways involved in fear and anxiety and are relevant to the study of...
Pages 82-97 Read Article
GENERAL PSYCHIATRY

Determinants of Complementary and Alternative Medicine Use by Patients with Bipolar Disorder

Amy M. Kilbourne, PhD, MPH, Laurel A. Copeland, PhD, John E. Zeber, PhD, Mark S. Bauer, MD, Elaine Lasky, RN, and Chester B. Good, MD, MPH
Objectives: We determined the prevalence and correlates of complementary and alternative medicine (CAM) use among patients with bipolar disorder. Methods: Patients with bipolar disorder recruited from a large urban mental health facility from 2004 to...
Pages 104-115 Read Article
GENERAL PSYCHIATRY

Predicting Antipsychotic Use in Children

Ken Gersing, MD, Bruce Burchett, PhD, JD, John March, MD, Truls Ostbye, MD, PhD, K. Ranga Rama Krishnan, MD
Psychotropic medications are increasingly being used by children and adolescents. In an earlier report, we noted that boys were receiving atypical antipsychotics more frequently than were girls (70% of the claims). Since diagnosis was not...
Pages 112-121 Read Article